The rise of the JN.1 variant indicates it might be more infectious or more adept at bypassing our immune defence compared to other variants according to the US Centre of Disease Control (CDC). Health authorities such as the Union Health Ministry of India, World Health Organization (WHO), and the US CDC suggest no significant increase in public health risk from the variant based on available evidence. WHO said current vaccines will continue to protect against severe disease and death from JN.1 variant. The holiday season has increased travel, along with diminishing immunity from previous COVID-19 infections may lead to more people experiencing illness. Even with milder symptoms, the widespread transmission of virus will strain people already dealing with other respiratory illnesses like flu, pneumonia and respiratory syncytial virus (RSV).
There is a need for emphasis on surveillance and precautionary measures in response to the detection of the variant in India, despite the absence of a call for panic. The current vaccines are seen to protect against severe disease and death.
